Diazoxide - search results

European Union - English - EMA (European Medicines Agency)

imprida hct

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

European Union - English - EMA (European Medicines Agency)

rasitrio

novartis europharm ltd. - aliskiren, amlodipine, hydrochlorothiazide - hypertension - cardiovascular system - rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.

European Union - English - EMA (European Medicines Agency)

riprazo hct

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.riprazo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.rirpozo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

European Union - English - EMA (European Medicines Agency)

sprimeo hct

novartis europharm ltd. - aliskiren, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension in adults.sprimeo hct is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.sprimeo hct is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.